Prescription drug · NDA
Zarontin (Ethosuximide) NDC 0071-0237
Ethosuximide 250 mg/1 · Capsule · Oral · Parke-Davis Div of Pfizer Inc
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 0071-0237-24 | 0007102372400071023724 | 100 CAPSULE in 1 BOTTLE (0071-0237-24)Marketed from Sep 22, 2000 |
How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Zarontin
- Generic name (nonproprietary)
- ethosuximide
- Active ingredients
- Ethosuximide — 250 mg/1
- Dosage form
- Capsule
- Route
- Oral
- Labeler
- Parke-Davis Div of Pfizer IncNDC labeler code 0071
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 012380
- Marketing start
- Listing expires
- Other FDA classes
- Decreased Central Nervous System Disorganized Electrical Activity (Physiologic effect)
- Identifiers
- Product ID 0071-0237_b5966080-3265-4027-b1f6-67af24097f18SPL ID b5966080-3265-4027-b1f6-67af24097f18SPL set ID 0e008f33-70a1-4bc6-b3a0-d45214418ab6RxCUI 197682, 201737UNII 5SEH9X1D1DUPC 0300710237247
- Pharmacologic class
- Anti-epileptic Agent
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N400071023724followed by a unit qualifier and the quantityPackage 00071-0237-24. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
INDICATIONS AND USAGE Zarontin is indicated for the control of absence (petit mal) epilepsy.
Excerpt only. Read the full label for complete information.
About NDC 0071-0237
- What is NDC 0071-0237?
- 0071-0237 is the product NDC for Zarontin (ethosuximide), Ethosuximide 250 mg/1 capsule, listed with the FDA by Parke-Davis Div of Pfizer Inc. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Zarontin (Ethosuximide).
- What is the active ingredient?
- Ethosuximide.
- Who is the labeler?
- Parke-Davis Div of Pfizer Inc, NDC labeler code 0071. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Zarontin?
- 1 other product NDC are listed under this name. See all Zarontin NDCs.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.
Related NDCs: other Zarontin products
Other finished products listed under the same name: strengths, forms and labelers.
| Product | Strength | Form · route | Labeler | Product NDC | Package NDCs (11-digit) |
|---|---|---|---|---|---|
| Zarontinethosuximide | Ethosuximide 250 mg/5mL | SolutionOral | Parke-Davis Div of Pfizer Inc | 0071-2418 | 00071-2418-19 |